TO THE EDITOR

Actinic keratosis (AK) is a precursor to cutaneous squamous cell carcinoma. Lengthy treatment duration and severe side effects have limited the therapeutic efficacy of the Food and Drug Administration—approved topical AK treatments (Cornejo et al., 2020). In addition, the efficacy of these treatments against hypertrophic AK is unclear. We previously showed the high efficacy of topical calcipotriol (a low-calcemic vitamin D3 analog) in combination with 5-fluorouracil (5-FU, an established topical AK treatment) for the elimination of AK in patients with multiple AKs at baseline in a randomized, double-blind clinical trial (Cunningham et al., 2017). To enable the comparison between calcipotriol plus 5-FU treatment outcomes and other recent AK treatments following the standard inclusion criteria (Blauvelt et al., 2021; Lebwohl et al., 2012), we performed an exploratory secondary analysis on our clinical trial data. In addition, we examined the impact of combination therapy on the clearance of hypertrophic AKs on the face. In our clinical trial, 64 subjects received 0.005% calcipotriol ointment plus 5% 5-FU cream (test) and 66 received Vaseline plus 5% 5-FU cream (control) twice-daily treatment for 4 consecutive days (Cunningham et al., 2017). Subjects underwent clinical evaluation before (day 0) and 8 weeks after treatment. In the original trial, the inclusion criteria were subjects with 4 to 15 clinically discrete and visible AKs within a 25 cm² contiguous area on the face, scalp, right upper extremity, and/or left upper extremity. The inclusion criteria for this study were subjects with a minimum of four to a maximum of 10 clinically typical, discrete, and visible AKs in a defined anatomical boundary within any of the treated sites: forehead, cheek (left and/or right), temples (combined), vertex of the scalp, and one-third distal portion of the forearm (left and/or right). In addition, we used the presence of any hypertrophic AKs on the face as inclusion criteria to assess the clearance rate for hypertrophic AKs on the face in the test versus the control group. Among eligible subjects, we compared the complete (100%) clearance, partial (≥75%) clearance, the percent clearance of AKs in each anatomical boundary, and the percent total clearance of hypertrophic AKs on the face at week 8 after treatment between the test and the control group in a blinded manner. Hypertrophic AK was defined as ≥6 mm hyperkeratotic papule or plaque on the treated skin. Hypertrophic and typical AKs were identified during the trial and documented in the annotated clinical images. Statistical significance was determined by Pearson’s chi-squared test (categorical) or two-sample t-test (continuous).

In this secondary analysis, 54 and 52 subjects were included in the test and control groups, respectively. In total, 24 subjects from the original trial were excluded in this secondary analysis because they had >10 AKs in the defined anatomical sites. No significant difference was noted between the two groups for age, sex, drug amount used, anatomical sites treated, and baseline AK counts on each site (Table 1). Calcipotriol plus 5-FU treatment showed a significantly higher complete (62% vs. 8%, P < 0.0001) and partial AK clearance (82% vs. 11%, P < 0.0001) for all anatomical sites combined in the test than in the control group (Table 2).

Table 1. Demographic and baseline clinical characteristics of the study subjects

| Characteristics | Calcipotriol + 5-FU (n = 54) | Vaseline + 5-FU (n = 52) | P-Value |
|-----------------|-----------------------------|--------------------------|---------|
| Age, mean (SD), y | 68.0 (6.9) | 70.4 (9.5) | 0.143 |
| Range | 51–88 | 52–89 | 0.316 |
| Sex, n (%) | Male 44 (81) | 46 (88) | 0.095 |
| Female | 10 (19) | 6 (12) | |
| Drug amount used, mean (SD), g | 15.42 (9.7) | 16.54 (9.2) | 0.547 |
| Baseline sites treated, n (%) | Forehead 37 (69) | 27 (52) | 0.047 |
| Temples | 18 (33) | 23 (44) | |
| Cheek | 11 (20) | 19 (37) | |
| Scalp | 25 (46) | 25 (48) | |
| Forearm | 16 (30) | 17 (33) | |
| Baseline actinic keratosis count on each site, median (IQR) | Forehead 8 (3) | 7 (4) | 0.073 |
| Temples | 5 (1) | 6 (3) | 0.698 |
| Cheek | 9 (2.5) | 7 (3) | 0.095 |
| Scalp | 6 (2) | 6 (2) | 0.544 |
| Forearm | 8 (6) | 8 (6) | 0.929 |

Abbreviations: 5-FU, 5-fluorouracil; IQR, interquartile range.

References

Cornejo et al., 2020. In

Citation

Cite this article as: JID Innovations 2022;2:100104 doi:10.1016/j.xjidi.2022.100104

© 2022 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 2. Complete and partial clearance of AKs in the study subjects

| Variable                  | Calcipotriol + 5-FU n/Total n (%) | Vaseline + 5-FU n/Total n (%) | P-Value | Difference (95% CI) |
|---------------------------|-----------------------------------|-------------------------------|---------|---------------------|
| Complete clearance        |                                   |                               |         |                     |
| All locations             | 66/107 (62)                       | 9/111 (8)                     | <0.0001 | 54 (42–63)          |
| Forehead                  | 26/37 (70)                        | 1/27 (4)                      | <0.0001 | 66 (44–78)          |
| Temples                   | 13/18 (72)                        | 3/23 (13)                     | 0.001   | 59 (29–77)          |
| Cheek                     | 8/11 (73)                         | 3/19 (16)                     | 0.0022  | 57 (20–77)          |
| Scalp                     | 15/25 (60)                        | 2/25 (8)                      | 0.0001  | 52 (26–70)          |
| Forearm                   | 4/16 (25)                         | 0/17 (0)                      | 0.0301  | 25 (1–49)           |
| Partial clearance         |                                   |                               |         |                     |
| All locations             | 88/107 (82)                       | 12/111 (11)                   | <0.0001 | 71 (60–79)          |
| Forehead                  | 35/37 (95)                        | 2/27 (7)                      | <0.0001 | 88 (68–94)          |
| Temples                   | 18/18 (100)                       | 3/23 (13)                     | <0.0001 | 87 (61–95)          |
| Cheek                     | 9/11 (82)                         | 3/19 (16)                     | 0.0005  | 66 (29–83)          |
| Scalp                     | 17/25 (68)                        | 4/25 (16)                     | 0.0002  | 52 (25–70)          |
| Forearm                   | 9/16 (56)                         | 0/17 (0)                      | 0.0004  | 56 (22–81)          |

Abbreviations: 5-FU, 5-fluorouracil; AK, actinic keratosis; CI, confidence interval.

Complete clearance was defined as 100% reduction and partial clearance as at least 75% reduction in the number of AKs in the treated anatomical site at 8 weeks after treatment.

the anatomical sites assessed in this analysis showed a significantly higher percent AK clearance in the test than in the control group (Figure 1a). The percent AK clearance was 87.4% versus 37.1% in 107 test versus 111 control anatomical sites combined (P < 0.0001). Likewise, percent AK clearance was significantly higher for each anatomical site in test than in the control group: forehead: 93.4% versus 33.5, P < 0.0001; temples: 94.8% versus 46.6, P < 0.0001; cheek: 90.2% versus 44.3, P = 0.0002; scalp: 83.4% versus 33.3, P < 0.0001; and forearm: 69.7% versus 27.2, P < 0.0001 (Figure 1a). In total, 33 subjects (13 in the test and 20 in the control group) were eligible for the assessment of their hypertrophic AKs. The percent total clearance of hypertrophic AKs on the face was significantly higher in the test than in the control group (54.0% vs. 14.7%, P = 0.002, Figure 1b). The cumulative number of hypertrophic AKs on the face was 50 in the test and 66 in the control group before treatment, which was reduced to 18 in the test and 52 in the control group after treatment (64% vs. 21.2% reduction, respectively, P < 0.0001).

The synergy between calcipotriol and 5-FU results in a novel and effective AK immunotherapy; however, further studies are required to determine whether this therapy can effectively prevent squamous cell carcinoma (Cunningham et al., 2017; Rosenberg et al., 2019). The results of this secondary analysis are consistent with the outcomes of our primary trial, which showed a higher complete and partial AK clearance on the face (27% vs. 0% and 80% vs. 0%, P < 0.0001 for both) in the test versus the control group, respectively (Cunningham et al., 2017). This study confirms the high efficacy of calcipotriol plus 5-FU immunotherapy for AK treatment using standard inclusion criteria and outcome measures that are comparable to other AK treatment studies (Blauvelt et al., 2021; Lebwohl et al., 2012). Specifically, topical application of ingenol mebutate gel versus placebo to a 25 cm² contiguous area on face and scalp once daily for 3 consecutive days led to complete and partial AK clearance of 42.2% versus 3.7% and 63.9% versus 7.4% (P < 0.001 for both), respectively (Lebwohl et al., 2012). Topical tirbanibulin ointment application to a 25 cm² contiguous area on face and scalp once daily for 5 consecutive days led to complete and partial AK clearance of 44% versus 5% and 68% versus 16% (P < 0.001 for both) in the test versus the placebo group, respectively (Blauvelt et al., 2021). Unlike these AK clinical trials, which compare the test treatment with placebo (Blauvelt et al., 2021; Lebwohl et al., 2012), we show the efficacy of 0.005% calcipotriol plus 5% 5-FU combination compared with 4 days of Vaseline plus 5% 5-FU. Future studies are required to compare this combination immunotherapy with the full course (i.e., 2–4 weeks) of 5% 5-FU monotherapy. In addition, a randomized clinical trial designed and powered to specifically investigate the efficacy of calcipotriol plus 5-FU immunotherapy for squamous cell carcinoma prevention is warranted. Finally, we show the high efficacy of calcipotriol plus 5-FU for the treatment of facial hypertrophic AKs. Future clinical trials with the standard inclusion criteria are needed to further validate and expand these findings.

Human study

The exploratory secondary analysis of clinical trial data was conducted in accordance with Massachusetts General Hospital (Boston, MA) and Washington University in St. Louis (St. Louis, MO) Institutional Review Board guidelines. Trial subjects provided written, informed consent.

Data availability statement

All data needed to evaluate the conclusions in the paper are present in the paper. No datasets were generated or analyzed during this study.

ORCIDs

Marjan Azin: http://orcid.org/0000-0001-6950-4854
Andrew R. Mahon: http://orcid.org/0000-0001-5842-3944
Steven Isaacman: http://orcid.org/0000-0001-7529-9440
Julia E. Seaman: http://orcid.org/0000-0003-2528-9880
Isabel E. Allen: http://orcid.org/0000-0001-9029-9744
Michael Szarek: http://orcid.org/0000-0002-0046-0264
Lynn A. Cornelius: http://orcid.org/0000-0002-6329-2819
AUTHOR CONTRIBUTIONS
Conceptualization: MA, LAC, SD; Data Curation: MA; Formal Analysis: MA, JES, IEA, MS; Investigation: MA, ABM, SI, JES, IEA, MS; Project Administration: SD; Supervision: SD; Writing - Original Draft Preparation: MA, SD; Writing - Review and Editing: ABM, SI, IEA, MS, LAC.

ACKNOWLEDGMENTS
This study was funded by PHD Biosciences. MA, JES, IEA, and MS received funding support from PHD Biosciences for this study.

CONFLICT OF INTEREST
LAC and SD are coinventors on a filed patent for the use of calcipotriol plus 5-fluorouracil for the treatment of precancerous skin lesions (PCT/US2015/049434). ABM is a chief scientific officer at PHD Biosciences. Washington University has a potential financial interest in PHD Biosciences through Option Agreement.

Marjan Azin1,2,3, Andrew B. Mahon4, Steven Isaacman4, Julia E. Seaman5, Isabel E. Allen5,6, Michael Szarek7,8,9, Lynn A. Cornelius10 and Shadmehr Demehri1,2,3,*

1Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; 2Center for Cancer Immunology, Mass General Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; 3Center for Cancer Research, Mass General Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; 4PHD Biosciences, San Diego, California, USA; 5Bay View Analytics, Oakland, California, USA; 6Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA; 7School of Public Health, SUNY Downstate Health Sciences University, Brooklyn, New York, USA; 8CPC Clinical Research, Aurora,
Colorado, USA; 9Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA; and 10Division of Dermatology, John T. Milliken Department of Internal Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA
*Corresponding author
e-mail: sdemehri1@mgh.harvard.edu

REFERENCES
Blauvelt A, Kempers S, Lain E, Schlesinger T, Tyring S, Forman S, et al. Phase 3 trials of tirbanibulin ointment for actinic keratosis. N Engl J Med 2021;384:e512–20.

Cornejo CM, Jambusaria-Pahlajani A, Willenbrink TJ, Schmults CD, Arron ST, Ruiz ES. Field cancerization: treatment. J Am Acad Dermatol 2020;83:719–30.

Cunningham TJ, Tabacchi M, Eliane JP, Tuchay SM, Manivasagam S, Mirzaalian H, et al. Randomized trial of calcipotriol combined with 5-fluouracil for skin cancer precursor immunotherapy. J Clin Invest 2017;127:106–16.

Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012;366:1010–9.

Rosenberg AR, Tabacchi M, Ngo KH, Wallendorf M, Rosman IS, Cornelius LA, et al. Skin cancer precursor immunotherapy for squamous cell carcinoma prevention. JCI Insight 2019;4:e125476.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/